Our Partnerships and Collaborations

VBI and Brii Bio have a license and collaboration agreement for the development of VBI-2601 (BRII-179) as part of a potential functional cure for chronic hepatitis B infection.

As part of their collaboration, CEPI will provide VBI up to $33M of funding to support development of VBI’s eVLP vaccine candidates against COVID-19 variants of concern, including B.1.351, the variant first identified in South Africa.

VBI and GSK have a collaboration to clinically evaluate the combination of VBI-1901, VBI’s cancer vaccine immunotherapeutic candidate, with GSK’s proprietary AS01 adjuvant system in patients with recurrent glioblastoma (GBM).

Through their Strategic Innovation Fund, the Government of Canada awarded VBI up to a CAD $56 million contribution to support the development of the Company’s prophylactic coronavirus vaccine candidates, VBI-2901 and VBI-2902, through Phase 2 clinical studies.

VBI and the NRC have a collaboration to develop a COVID-19 vaccine candidate and a pan-coronavirus vaccine candidate, targeting COVID-19, severe acute respiratory syndrome (SARS), and Middle East respiratory syndrome (MERS). This is the latest collaboration in a series of collaborations with the NRC, which have included research and development on a number of preclinical programs.

(previously Therapure Biopharma Inc.)

VBI and Resilience have an agreement for the development and manufacturing services in preparation for production of its coronavirus vaccine candidates. The collaboration is expected to support clinical studies through Phase 2 clinical development.

VBI and Syneos Health have a partnership for commercialization of VBI’s 3-antigen prophylactic hepatitis B vaccine candidate in the United States, Europe, and Canada, pending regulatory approvals.